Title: Pilot testing a model of psychological care for heart transplant recipients

Abstract

Background: Anxiety and depression are common after heart transplantation. This study aimed to pilot test the feasibility of a clinical model of psychological care for heart transplant recipients. The model of care involved nurse-led screening for anxiety and depression followed by referral for a course of telephone-delivered cognitive behaviour therapy as well as co-ordination of communication with on-going specialist and primary care services.

Methods: A pilot randomised controlled trial was conducted. Heart transplant recipients who self-reported at least mild anxiety or depressive symptoms were randomised (defined as a score higher than 5 on the Patient Health Questionnaire-9 or the Generalized Anxiety Disorder-7 [GAD-7], or a score higher than 20 on the Kessler Psychological Distress Scale [K10]). The primary outcome was assessment of feasibility of conducting a larger trial, which included identification of recruitment and attrition rates as well as the acceptability of the intervention. Follow-up was conducted at 9 weeks and 6 months.

Results: One hundred twenty-two of the 126 (97 %) heart transplant recipients assessed on their attendance at the outpatient clinic met the study eligibility criteria. Of these patients, 88 (72 %) agreed to participate. A moderate proportion of participants (n = 20; 23 %) reported at least mild symptoms of anxiety or depression. Five participants were excluded because they were currently receiving psychological counselling, two withdrew before randomisation and the remaining 13 were randomised (seven to intervention and six to usual care). The majority of the randomised participants were male (n = 9; 69 %) and aged over 60 (range 35–73). Median length of time post-transplant was 9.5 years (ranging from 1 to 19 years). On enrolment, 3 randomised participants were taking anti-depressants. One intervention group participant withdrew and a further 3 (50 %) declined the telephone-delivered CBT sessions; all because of restrictions associated with physical illnesses. Attrition was 30 % at the 6 month follow-up time-point.

Conclusions: Due to the poor acceptability of telephone-delivered cognitive behavioural therapy observed in our sample, changes to intervention components are indicated and further pilot testing is required.

Trial registration: ACTRN12613000740796 Date registered: 03/07/2013.

Keywords: Depression, Anxiety, Transplantation, Cognitive behavioural therapy, Psychological, Screening
that psychological intervention resulted in moderate improvements in depression and anxiety in patients with coronary heart disease [4]. Also of note, the largest randomised controlled trial of CBT in patients with cardiovascular disease, which randomised 2481 patients post-myocardial infarction, reported that the improvement in psychosocial outcomes at 6 months favoured the group that received counselling (mean [SD] change -10.1 [7.8] vs. -8.4 [7.7]; p < 0.01) [5]. This evidence suggests that CBT is likely to decrease anxiety and depression symptoms for heart transplant recipients and therefore should be considered for formal evaluation in a controlled trial.

The ISHLT also recommends: that each heart transplant team should include a psychologist because multidisciplinary treatment teams are better prepared to address psychosocial risk factors for poor outcomes after heart transplantation; that depressive symptoms should be regularly evaluated during follow-up of heart transplant recipients using validated screening instruments; and that all patients who screen positive for symptoms of depression should be referred for specialized treatment [6]. It should be noted, though, that these recommendations are based on consensus. High level evidence demonstrating the benefit of these interventions on heart transplant recipient outcomes is required. For this reason, it was decided to pilot test the feasibility of a model of care that operationalizes these recommendations with the view towards conducting a larger clinical trial. The key features of the model of care that align with the ISHLT recommendations pilot tested in the study reported in this paper include:

- Screening for psychological symptoms;
- Referral for specialized treatment (CBT) for patients with elevated psychological symptoms; and
- Involvement of a multidisciplinary team, including nurses, psychologists, heart transplant physicians and General Practitioner/Primary care providers.

**Methods**
A pilot randomised controlled trial was conducted. Human research ethics committee and institutional approval was granted for the study (HREC13QPCH239; 130000686). It was registered prospectively with the Australian New Zealand Clinical Trials Registry (ACTRN12613000740796).

**Outcomes**
The primary outcome of this study was the feasibility of conducting a larger clinical trial. Assessment of feasibility included recruitment issues, likely attrition rates and acceptability of interventions, which are important considerations in planning a larger clinical trial. A planned secondary outcome was to evaluate the potential efficacy of the intervention.

**Participants**
Heart transplant recipients aged over 18 years who were scheduled for a routine outpatient consultation with the Heart Transplant Nurse Practitioner at a major metropolitan hospital in Australia were eligible to participate in the study. Patients less than 3 months post-transplant as well as those who were cognitively impaired (as confirmed by a treating clinician), unable to understand and speak English, had a diagnosed major psychiatric comorbidity (schizophrenia, bipolar, dementia) or had a terminal illness (such as cancer) were excluded. Participants who reported at least mild symptoms of anxiety, depression or psychological distress but who were not currently receiving regular psychological therapy from a mental health practitioner were randomised to intervention or control groups.

**Procedure**
Prior to their consultation with the Nurse Practitioner, consenting participants completed questionnaires to measure the severity of symptoms commonly associated with anxiety and depression (Patient Health Questionnaire-9 [PHQ-9], Generalized Anxiety Disorder-7 [GAD-7], Kessler Psychological Distress Scale [K10]) as well as questionnaires to evaluate quality of life (Short Form-36 [SF-36]), transplant-specific self-care (Transplant Care Index [TCI], immunosuppression adherence (Basel Assessment of Adherence to Immunosuppressive Medications Scale [BAASIS]) and symptom occurrence and distress (Modified Transplant Symptom Occurrence and Symptom Distress Scale [MTSOSD-R]). The PHQ-9, GAD-7 and K10 results were made available to the Nurse Practitioner during the clinic visit so that usual clinical advice and referrals for patients experiencing psychological distress could be actioned. Participants with scores over 5 on the GAD-7 or PHQ-9 or scores over 20 on the K10 (indicating at least mild anxiety or depressive symptoms) were randomised to the intervention or control group.

**Intervention**
All randomised participants received usual care, which involved receiving routine clinical advice from the Heart Transplant Nurse Practitioner for patients identified as experiencing psychological distress as well as a letter to the participant’s General Practitioner advising them of the severity of psychological symptoms and their participation in the study.

Participants randomised to the intervention group were also offered:

- eight telephone-delivered CBT sessions, of about 60 min, delivered by a Doctor of Clinical Psychology student (under the supervision of an accredited Clinical Psychologist); followed by.
prospective 1-year virologic failure \[14, 15\].

Cut points of 5, 10, and 15 representing mild, moderate, and severe levels of depression have been defined for this instrument \[8\].

### Generalized anxiety disorder 7-item scale

The Generalized Anxiety Disorder 7-item scale (GAD-7) is a self-reported measure of anxiety. Higher scores indicate higher levels of anxiety. Participants were asked to consider the preceding 2 weeks and rate symptom frequency as not at all (0), several days (1), more than half of all days (2) or nearly all days (3). Cut points of 5, 10, and 15 representing mild, moderate, and severe levels of anxiety have been defined for the GAD-7 \[9\].

### Kessler psychological distress scale (K-10)

The Kessler Psychological Distress Scale (K-10) measures psychological distress. It is used frequently in research and clinical practice to screen for psychological disorders. The 10 items measure severity of anxiety and depression symptoms using a 5-point Likert type scale. The K-10 strongly discriminates between community cases and non-cases of DSM-IV psychological disorders \[10\]. A cut-off score of 20 had a sensitivity of 0.66 and specificity of 0.92 for detecting a current anxiety or affective disorder in a population-based survey \[11\].

### Medical outcomes short form-36 health survey

The Medical Outcomes Short Form-36 Health Survey (SF-36) yields an 8-scale profile of self-reported functional health and well-being. Higher scores indicate a better health status \[12\]. The domains of quality of life measured by the SF-36 are physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain and general health.

### Basel assessment of adherence to immunosuppressive medications scale

The Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) consists of 4 items that measure the ingestion and timing of medications, drug holidays and dose reductions. Non-adherence can be defined as non-adherence on any of the 4 items \[13\]. The BAASIS also assesses overall adherence using a visual analogue scale (VAS) scale ranging from 0 (never took medications as prescribed) to 100 (always took medications as prescribed). This instrument has sensitivity of 87.5 % and specificity of 78.6 % compared to prospective 1-year virologic failure \[14, 15\].
**Transplant care index**

The Transplant Care Index (TCI) consists of 6 items rating difficulty in self-care, specifically in relation to transplant-related factors such as attending scheduled health care consultations, following recommended patterns of nutrition and exercise, having scheduled pathology tests, adhering to the prescribed medication regimen and dealing with medication side effects. This instrument demonstrated acceptable internal consistency (Cronbach’s alpha 0.76–0.82) in a sample of 598 renal transplant recipients [16].

**Modified transplant symptom occurrence and symptom distress-revised**

The Modified Transplant Symptom Occurrence and Symptom Distress-Revised (MTSOSD-R) was developed to assess occurrence and distress experienced by the side effects of immunosuppression medications. Content validity, construct validity and discriminant validity of the instrument were substantiated in a study of 108 renal transplant recipients [17, 18]. A subsequent study undertaken with 216 heart transplant recipients demonstrated the internal consistency of this scale. Internal consistency was high for the symptom occurrence (.947) and symptom distress (.984) subscales [19].

**Allocation sequence generation and concealment method**

A computer generated table of random sequence was used to randomly allocate participants to one of two conditions (intervention/control). Sealed, sequentially numbered envelopes concealed the randomisation sequence.

**Statistical analysis**

Descriptive statistics were used to assess recruitment rates, intervention acceptability and attrition. As per our protocol, it was intended to randomise 30 patients to intervention or control groups in this study because it was expected that this sample would have been sufficient to provide preliminary data to understand the feasibility of the intervention and determine effect size for sample size estimation to adequately power a future larger clinical trial. However, due to the smaller than anticipated number of recruited participants and high proportion of participants randomised to the intervention group not completing the protocol, we could not perform these planned analyses. Descriptive statistics were calculated to describe the characteristics of participants in the study at baseline. Changes in psychological symptom severity from baseline to follow-up were calculated for individual participants but not compared between the intervention and control groups.

**Results**

**Recruitment**

A CONSORT flowchart is presented in Fig. 1. From January to September 2014, 122 of the 126 (97 %) heart transplant recipients assessed on their attendance at the outpatient clinic met the study eligibility criteria. Of these patients, 88 (72 %) agreed to participate. A moderate proportion of participants (n = 20; 23 %) reported at least mild symptoms of anxiety or depression. Five of these participants were excluded because they were currently receiving psychological counselling, two withdrew before randomisation and the remaining 13 were randomised.

**Participant characteristics at baseline**

An overview of demographic and clinical characteristics of the intervention and control groups is presented in Table 1. The majority of the randomised participants were male (n = 9; 69 %) and aged over 60 (range 35–73). Median length of time post-transplant was 9.5 years (ranging from 1 to 19 years). On enrolment, 3 randomised participants were taking anti-depressants. A summary of intervention and control group participants’ health-related quality of life, immunosuppression-related symptom prevalence and treatment adherence is presented in Table 2. Most randomised participants generally did not report difficulties with adherence with immunosuppression therapy (Median score of 98 out of a possible 100 on the BAASIS measure of self-reported overall treatment adherence; Interquartile range 95–100). The majority of the sample reported poor health-related quality of life, with a median score of 50 of a possible 100 for the ‘General Health’ domain of the SF-36 (IQR 50–55).

**Acceptability of intervention components**

After randomisation, one participant from the intervention group withdrew from the study. A further 3 (50 %) of the intervention participants declined the telephone-delivered CBT sessions; all because of restrictions associated with physical illness. Two intervention participants (33 %) completed the CBT sessions. Neither of these participants had a history of a diagnosed anxiety or depression disorder. A case conference with one of the intervention participant’s general practitioners could not be scheduled at a time that suited all members of the transplant team. The other intervention participant who completed the course of CBT requested that the case conference not be conducted. Written reports from the psychologist were circulated instead.

**Attrition**

All participants who had not withdrawn from the study completed the follow-up questionnaires at 9 weeks after screening. One participant (16 %) in the intervention
group and two participants (29%) in the control group were not able to be contacted for 6 month follow-up.

**Changes in severity of psychological symptoms**
Psychological symptoms measured with the PHQ-9 and GAD-7 of the two participants (33%) who completed the course of CBT reduced to scores below 5 at follow-up conducted at 9 weeks post-screening. All intervention group participants who declined CBT (n = 3; 67%) still reported psychological symptoms with a score greater than 5 on the PHQ-9 or GAD-7 at the 9 week follow-up (n = 1 withdrew after randomisation). Four (57%) of the seven control group participants still experienced symptoms with a score greater than 5 on the PHQ-9 or GAD-7 at the 9 week follow-up. At 6 month follow-up, two participants (40%) in the control group reported psychological symptoms with a score greater than 5 on the PHQ-9 or GAD-7 (two participants were lost to follow-up). All participants in the intervention group who completed the follow-up questionnaire at 6 months after screening reported PHQ-9 and GAD-7 scores <5 (n = 4; 1 participant had withdrawn and one participant could not be contacted).

**Table 1** Baseline demographic and clinical characteristics

| Variable                              | Intervention  | Control     |
|---------------------------------------|---------------|-------------|
|                                       | Median (range) | Median (range) |
| Age                                   | 57 (43–70)    | 61 (35–73)  |
| Male                                  | 4 (67)        | 5 (71)      |
| Years since transplant                | 9 (2–19)      | 10 (1–18)   |
| Number of comorbidities               | 8 (3–8)       | 8 (7–10)    |
| History of anxiety or depression disorder | 3 (50)       | 1 (14)      |
| Taking anti-depressants               | 1 (14)        | 2 (29)      |

Conway et al. BMC Nursing (2016) 15:62 Page 5 of 8
Table 2 Baseline severity of psychological and immunsuppression-related symptoms and levels of health-related quality and treatment adherence

| Variable                              | Intervention n = 6 | Control n = 7 |
|---------------------------------------|--------------------|---------------|
| PHQ-9 score                           | 9 (7–13)          | 10 (8–18)     |
| GAD-7 score                           | 4.5 (2–7)         | 8 (7–10)      |
| K-10 score                            | 19.5 (17–21)      | 20 (16–25)    |
| Difficulty with keeping scheduled     | 5 (4–5)           | 4 (4–5)       |
| follow-up visits\(^d\)                |                   |               |
| Difficulty with following a regular   | 2.5 (1–4)         | 2 (1–3)       |
| exercise program\(^c\)                |                   |               |
| Difficulty with following a healthy   | 4 (2–4)           | 2 (2–3)       |
| and balanced diet\(^b\)               |                   |               |
| Difficulty with having tests done     | 5 (5–5)           | 4 (4–5)       |
| as scheduled\(^c\)                    |                   |               |
| Difficulty with taking all medicines  | 5 (5–5)           | 4 (4–5)       |
| as prescribed\(^c\)                   |                   |               |
| Difficulty with side effects of       | 4.5 (2–5)         | 4 (3–4)       |
| medicines\(^a\)                       |                   |               |
| Immunosuppression treatment           | 100 (100–100)     | 95 (90–98)    |
| adherence\(^c\)                       |                   |               |
| Number of immunsuppression-related    | 6.5 (3–12)        | 7 (3–12)      |
| symptoms experienced ‘almost always’  |                   |               |
| or ‘always’\(^b\)                     |                   |               |
| Physical functioning\(^e\)            | 70 (25–95)        | 40 (15–55)    |
| Role limitations due to              | 50 (0–75)         | 25 (0–75)     |
| physical health\(^c\)                 |                   |               |
| Role limitations due to emotional    | 0 (0–100)         | 100 (0–100)   |
| problems\(^c\)                        |                   |               |
| Energy/fatigue\(^e\)                 | 27.5 (5–50)       | 30 (20–35)    |
| Emotional well-being\(^c\)           | 70 (64–72)        | 60 (60–64)    |
| Social functioning\(^c\)             | 50 (50–63)        | 50 (50–50)    |
| Pain\(^e\)                            | 36 (33–48)        | 50 (35–58)    |
| General health\(^c\)                 | 53 (50–55)        | 50 (40–50)    |

IQR interquartile range, \(^a\)Rating of overall treatment adherence over the past 2 weeks on a scale of 0–100 (higher score = better adherence); \(^b\)MTOSOSD-59; \(^c\)Scores range from 0 to 100 with higher scores representing better health-related quality of life; \(^d\)1 = Very difficult, 5 = Very easy; \(^e\)PHQ-9 = Patient Health Questionnaire 9-item scale; GAD-7 = Generalized Anxiety Disorder 7-item scale; K-10 = Kessler Psychological Distress Scale

Discussion

The main finding of this pilot study is that the majority of heart transplant recipients who reported at least mild symptoms of anxiety or depression on screening at their routine outpatient appointment but were not currently receiving psychological counselling did not accept a telephone-delivered CBT intervention. Results may reflect the broader difficulties in treating mental health problems stemming from perceived risk of stigmatisation associated with being diagnosed with a psychological disorder [20]. However, participants’ decisions to accept psychological treatment may also have been influenced by the unique experiences associated with heart transplantation. Qualitative studies have identified that competing senses of hope and gratitude mixed with guilt and grief regarding the acceptance of a heart from a deceased donor may contribute to anxiety and depression in this population [21]. In this regard, a noteworthy finding is that the acceptability of telephone-delivered CBT was worse in our sample of heart transplant recipients compared with other chronic disease populations. For example, the MoodCare study similarly involved a course of telephone-delivered CBT for patients hospitalised with acute coronary syndrome who reported depressive symptoms with a PHQ-9 score more than 5 [22]. Yet in the Mood Care study, 61 % of the 61 participants who were randomised to the intervention group completed five or more CBT sessions and the median number of sessions was eight [22]. It should be noted, though, that 32 % of participants in the Mood Care study who were eligible for inclusion based on initial screening that took place in hospital either withdrew or were lost to follow-up at a second screening undertaken just prior to randomisation [22]. Future trials involving psychological interventions for heart transplant recipients should therefore consider utilising a two-stage screening process to confirm participants’ intentions in taking part in CBT before randomisation.

Due to the poor acceptability of telephone-delivered CBT observed in our sample, changes to intervention components are indicated and further pilot testing should be conducted before proceeding to a clinical trial of a psychological intervention for heart transplant recipients with anxiety or depression. One change to consider piloting would be to raise the screening cut-off scores. Alongside this pilot study, we evaluated the validity and reliability of the PHQ-9, GAD-7 and K-10 for detection of anxiety or depression. Full details are reported elsewhere (under review). It was identified that the optimal cut-off score for detecting depression was a score of 10, which is considerably higher than the score we used for eligibility to be randomised to CBT in the pilot study. Moreover, it is known that PHQ-9 scores may include a small amount of variance from somatic symptoms not related to depression [23]. For these reasons, it is not surprising that some intervention group participants declined CBT due to physical illness. These participants may have accumulated a PHQ-9 score >5 due to the severity of somatic symptoms contained within the PHQ-9 that were not necessarily caused by depression, such as fatigue and sleep disturbance. An alternative to raising the cut-off score in an effort to decrease false-positive screening is to conduct a structured psychological interview with heart transplant recipients who screen positive for a potential psychological disorder. Psychological interventions can then be targeted at only those heart transplant recipients who meet criteria for a psychological disorder.
A further alternative, which would be prudent to investigate based on results from this pilot study that indicated a 2-month period of counselling was not acceptable to most participants, is to consider the use of nurse-led brief interventions to improve psychological outcomes for heart transplant recipients. A nurse-led CBT intervention has been shown to be accepted well by hospitalised heart failure patients. In a randomised controlled trial, hospitalised heart failure patients who reported mild-moderate symptoms of depression as indicated by Beck Depression Inventory scores of 10–20 were randomised to usual care or a single, nurse-delivered, 30-min, one-on-one cognitive therapy session that took place in a hospital followed by a 5–10 min telephone ‘booster’ that was conducted 1 week after discharge [24]. In this study, 20 of the 21 patients randomised to the intervention group received the allocated intervention [24].

It was planned to investigate the potential efficacy of the intervention on health-related quality of life, severity and distress of immunosuppression-related symptoms and treatment adherence by calculating effect sizes. However, this was not conducted due to the smaller than anticipated sample size. Reassuringly, both participants who received CBT as part of the study had remission of their symptoms after the end of the 8-week course of counselling. This is consistent with the previous literature in other populations that has overwhelmingly demonstrated that CBT reduces the severity of psychological symptoms and that telephone-delivered CBT is equally as effective as a face to face counselling strategy [25, 26].

A limitation of this pilot study to consider is that it was conducted at only one transplantation centre. Also, selection bias might have influenced the results. Heart transplant recipients suffering from anxiety or depression may have been less inclined to participate in the research [27]. Heart transplant recipients were also screened for the presence of anxiety or depression only once during the data collection period, even if they attended the outpatient clinic multiple times over that period. Potentially, screening at each attendance would have increased detection of anxiety or depression.

**Conclusions**

Results from our study indicated that many heart transplant recipients who might have benefited from psychological intervention did not accept treatment in the form of telephone-delivered CBT. It is unknown whether or not other modes of delivering CBT (face to face or online) would be more or less acceptable. These are potential areas to consider pursuing in further research aimed at improving psychological outcomes for heart transplant recipients. Due to the poor acceptability of telephone-delivered CBT observed in our sample, changes to intervention components are indicated and further pilot testing should be conducted before proceeding to a large clinical trial of a psychological intervention for heart transplant recipients with anxiety or depression.

**Additional files**

**Additional file 1:** Dataset. (XLS 27 kb)

**Abbreviations**

BAASIS: Basel assessment of adherence to immunosuppressive medications scale; CBT: Cognitive behavioural therapy; GAD-7: Generalized anxiety disorder-7; IQR: Interquartile range; ISHLT: International society for heart and lung transplantation; K10: Kessler psychological distress scale; MTSOSD-7: Modified transplant symptom occurrence and symptom distress scale; PHQ-9: Patient health questionnaire-9; SF-36: Medical outcomes short form health survey-36; TCI: Transplant care index

**Acknowledgements**

None.

**Funding**

This study was conducted with funding from the Institute of Health and Biomedical Innovation at Queensland University of Technology and the Sigma Theta Tau International Honour Society of Nursing.

**Availability of data and materials**

All data generated or analysed during this study are included in this published article (and its Additional file 1).

**Authors’ contributions**

AC, JS, JM, PF made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; AC drafted the manuscript; JS, JM, PF, revised critically the manuscript for important intellectual content; AC, JS, JM, PF have given final approval of the version to be published.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Human research ethics committee and institutional approval was granted for the study (HREC13QPCH239; 1300000686). Participants provided written consent.

**Author details**

1Institute of Health and Biomedical Innovation, Queensland University of Technology (QUT), 60 Musk Ave, Kelvin Grove, QLD 4059, Australia. 2School of Psychology, Queensland University of Technology (QUT), Brisbane, Australia. 3Advanced Heart Failure and Transplant Unit, The Prince Charles Hospital, Chermside, Australia. 4Nursing Research and Practice Development Centre, The Prince Charles Hospital & School of Nursing, Midwifery and Paramedicine, Australian Catholic University, Sydney, Australia.

Received: 24 February 2016 Accepted: 12 October 2016 Published online: 26 October 2016

**References**

1. Cupples S, Dew MA, Grady KL, et al. Report of the Psychosocial Outcomes Working Group of the Nursing and Social Sciences Council of the International Society for Heart and Lung Transplantation: Present status of research on psychosocial outcomes in cardiothoracic transplantation: Review and recommendations from the field. J Heart Lung Transplant. 2006;25:716–25.
2. Beck JS and Beck AT. Cognitive behavior therapy. New York Basics and beyond. Guilford Publication, 2011.
3. Butler AC, Chapman JE, Forman EM, Beck AT. The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev. 2006;26:17–31.

4. Whalley B, Thompson DR and Taylor RS. Psychological Interventions for Coronary Heart Disease: Cochrane Systematic Review and Meta-analysis. Int J Behav Med. 2014;21:109–121.

5. Berkman L, Burg M, Carney R, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhanced recovery in coronary heart disease patients (ENRCHD) randomized trial. J Am Med Assoc. 2003;289:3106–16.

6. Costanzo MR, Dipchand A, Starling R, et al. The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29:914–56.

7. Beck AT. Cognitive therapy of depression. New York: The Guilford Press, 1979.

8. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD. J Am Med Assoc. 1999;282:1737–44.

9. Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092.

10. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med. 2002;32:959–76.

11. Andrews G, Slade T. Interpreting scores on the Kessler psychological distress scale (K10). Aust N Z J Public Health. 2001;25:494–7.

12. Garatt A, Schmidt L, Mackintosh A, Fitzpatrick R. Quality of life measurement: bibliographic study of patient assessed health outcome measures. Br Med J. 2002;324:1417.

13. Doesch A, Mueller S, Konstandin M, et al. Increased adherence after switch from twice daily calcineurin inhibitor based treatment to once daily modified release tacrolimus in heart transplantation: a pre-experimental study. Transplant Proc. 2010;42:4238–42. Elsevier.

14. Glass TR, De Geest S, Hirschel B, et al. Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther. 2008:13:77.

15. Deschamps AE, De Geest S, Vandamme A-M, Bobbaers H, Peetermans WE, Wijngaerden EV. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS Patient Care STDs. 2008;22:735–43.

16. Matas AJ, Halbert R, Barr ML, et al. Life satisfaction and adverse effects in renal transplant recipients: a longitudinal analysis. Clin Transpl. 2002;16:113–21.

17. Moons P, De Geest S, Versteven K, et al. Psychometric Properties of the Modified Transplant Symptom Occurrence and Symptom Distress Scale. J Nurs Meas. 2001;9:115–23.

18. Dobbels F, Moons P, Abraham I, Larsen CP, Dupont L, De Geest S. Measuring symptom experience of side-effects of immunosuppressive drugs: the Modified Transplant Symptom Occurrence and Distress Scale. Transplant. Int. 2008;21:764–73.

19. Stiefel P, Malehsa D, Bara C, Stuebeier M, Haverich A, Kugler C. Symptom experiences in patients after heart transplantation. J Health Psychol. 2013;18:680–92.

20. Bijl RV, Ravelli A. Psychiatric morbidity, service use, and need for care in the general population: results of The Netherlands Mental Health Survey and Incidence Study. Am J Public Health. 2000;90:602–7.

21. Conway A, Schadewaldt V, Clark R, Ski C, Thompson DR, Doering L. The psychological 11 experiences of adult heart transplant recipients: a systematic review and meta-summary of qualitative findings. Heart Lung. 2013;42:449–55.

22. O’Neill A, Taylor B, Sanderson K, et al. Efficacy and feasibility of a tele­health intervention for acute coronary syndrome patients with depression: Results of the “MoodCare” randomized controlled trial. Ann Behav Med. 2014;48:163–74.

23. Leavens A, Patten SB, Hudson M, Baron M, Thoms BD. Influence of somatic symptoms on patient health questionnaire-9 depression scores among patients with systemic sclerosis compared to a healthy general population sample. Arthritis Care Res. 2012;64(11):1195–201.

24. Dekker RL, Moser DK, Pedersen AR, Lennie TA. Cognitive therapy improves three-month outcomes in hospitalized patients with heart failure. J Card Fail. 2012;18:10–20.

25. Muller I, Yardley L. Telephone-delivered cognitive behavioural therapy: a systematic review and meta-analysis. J Telemed Telecare. 2011;17:177–84.